Prashant Chandrasekaran

Prashant Chandrasekaran

Auto-generated profile, based on publicly available information

Prashant Chandrasekaran

Division of Cardiology, Department of Pediatrics, University of Pennsylvania, The Children’s Hospital of Philadelphia, Philadelphia, PA, USA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 October 2022 in Development
Verified
Journal Article
Open access
PDF file
PCPrashant Chandrasekaran
Prashant Chandrasekaran
NNNicholas Negretti
Nicholas Negretti
ASAravind Sivakumar
Aravind Sivakumar
DLDerek C. Liberti
Derek C. Liberti
HWHongbo Wen
Hongbo Wen
DFDavid B. Frank
David B. Frank
There is a growing amount of data uncovering the cellular diversity of the pulmonary circulation and mechanisms governing vascular repair after injury. However, the molecular and cellular mechanisms contributing to the morphogenesis and growth of the pulmonary vasculature during embryonic development are less clear. Importantly, deficits in vascular development lead to significant pediatric lung diseases, indicating a need to uncover fetal programs promoting vascular growth. To address this, we used a transgenic mouse reporter for expression of Cxcl12, an arterial endothelial hallmark gene, and performed single-cell RNA sequencing on isolated Cxcl12-DsRed+ endothelium to assess cellular heterogeneity within pulmonary endothelium. Combining cell annotation with gene ontology and histological analysis allowed us to segregate the developing artery endothelium into functionally and spatially distinct subpopulations. Expression of Cxcl12 is highest in the distal arterial endothelial subpopulation, a compartment enriched in genes for vascular development. Accordingly, disruption of CXCL12 signaling led to, not only abnormal branching, but also distal vascular hypoplasia. These data provide evidence for arterial endothelial functional heterogeneity and reveal conserved signaling mechanisms essential for pulmonary vascular development.

1 May 2022 in bioRxiv
Verified
Preprint
Open access
PDF file
PCPrashant Chandrasekaran
Prashant Chandrasekaran
NNNicholas Negretti
Nicholas Negretti
ASAravind Sivakumar
Aravind Sivakumar
MNMaureen Peers de Nieuburgh
Maureen Peers de Nieuburgh
JWJoanna Wang
Joanna Wang
DFDavid B. Frank
David B. Frank
In adults, there is a growing amount of data uncovering the cellular diversity of the pulmonary circulation and mechanisms governing vascular repair after injury, however, molecular and cellular mechanisms contributing to the morphogenesis and growth of the pulmonary vasculature during embryonic development are less clear. Importantly, deficits in vascular development lead to a large number of lung diseases in children, indicating a need to uncover fetal programs that promote pulmonary vascular growth. To address this, we used a transgenic mouse reporter for expression of Cxcl12 , an arterial hallmark gene, and performed single-cell RNA sequencing on isolated Cxcl12 -DsRed+ endothelium to assess cellular heterogeneity within pulmonary endothelium. Combining cell annotation, gene ontology analysis, and spatial transcriptomics allowed us to segregate the developing artery into spatially and functionally distinct novel subpopulations. In addition, expression of Cxcl12 suggests a morphogen gradient from arteries to capillaries, suggesting directed cell migration for pulmonary vascular development. Disruption of this gradient led to abnormal branching and pulmonary vascular hypoplasia. These data provide evidence for arterial endothelial functional heterogeneity and reveal conserved signaling mechanisms essential for pulmonary vascular development.

16 July 2021
Verified
Thesis
Closed access
PCPrashant Chandrasekaran
Prashant Chandrasekaran
LHLin Han
Lin Han
Temporomandibular joint (TMJ) disorders, or TMD, refers to a group of clinical disorders that affect the TMJ and its associated structures. TMJ Osteoarthritis (TMJ OA) is a major subtype of TMDs, which affects 10-16% of the population exhibiting TMD and is secondary to disc displacement, trauma, developmental abnormalities and overload on the joint. Degeneration of mandibular condyle cartilage is a major hallmark of TMJ OA and degradation of its extracellular matrix (ECM) has been identified as a key feature of TMJ OA. Therefore, it is critical to understand the changes in the ECM and identify the molecular mechanisms governing TMJ OA progression, which can provide a foundation for developing early detection and repair strategies. In the first part of the dissertation, we define the biomechanical and structural properties of murine TMJ articular disc and condyle cartilage in the normal joint (wild-type, WT), and delineate the roles of type V collagen (collagen V) in 3-month-old collagen V heterozygous (Col5a1+/-) mice using atomic force microscopy (AFM)-based nanomechanical tools and electron microscopy. By evaluating 3-month-old WT mice, we reported that the condyle fibrocartilage exhibits significantly higher modulus compared to all five regions of both superior and inferior disc. We further quantified the regional specific micromoduli on both sides of the disc. This knowledge will serve as a benchmark for understanding TMJ biomechanical function and documenting disease pathogenesis in various murine models. Indeed, we reported compromised biomechanical properties and significantly thicker collagen I fibrils on the fibrocartilage layer of the Col5a1+/- condyle. Collagen V is a regulatory fibril-forming collagen, that is involved in the collagen I fibril assembly. In addition to its expected role in regulating the fibrocartilage layer, this dissertation uncovered a new role of collagen V in secondary hyaline cartilage of TMJ condyle, where we identified similar phenotype in this collagen II-dominated region. Collagen V is clinically important as its mutation causes classical Ehlers-Danlos Syndrome (cEDS), a connective tissue disorder. Thus, this study will provide further insights into higher prevalence of TMJ OA in patients suffering from cEDS. The second part of the dissertation investigates susceptibility of Col5a1+/- mice to TMJ OA. To demarcate the roles of collagen V in TMJ OA, we applied the unilateral anterior crossbite prosthesis (UAC) procedure to induce aberrant TMJ loading to Col5a1+/- mice. Three weeks after UAC, Col5a1+/- mice exhibited reduction in the modulus of the condyle fibrocartilage layer and an increase in aggrecan staining in the underlying hyaline cartilage, in addition to significant changes to cell arrangement in comparison to WT. These signs together led to higher Mankin OA scores, signifying increased susceptibility to condyle degradation. In the final section, we further investigate the age-specific impact of collagen V deletion in post-natal joint development using collagen V inducible knockout mice (Col5a1iKO). By deleting the collagen V expression at 1 week and 1 month of age, we revealed different developmental roles for collagen V in both articular disc and mandibular condyle. These results highlight the importance of collagen V in serving as an indispensable constituent to the structural and functional integrity of TMJ condyle ECM, and provides a basis for developing collagen V-based TMJ condyle regeneration and repair strategies to ameliorate TMJ OA.

14 October 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
PCPrashant Chandrasekaran
Prashant Chandrasekaran
SMSylvia N. Michki
Sylvia N. Michki
JPJennifer Pogoriler
Jennifer Pogoriler
QWQuinn Wright
Quinn Wright
MLMinQi Lu
MinQi Lu
DFDavid B. Frank
David B. Frank
Rationale: Pulmonary veno-occlusive disease (PVOD) is a progressive and lethal disease cured only lung transplant. While genetic mutations in EIF2AK4 have been identified in some cases, 70% of PVOD patients have no known etiology. Objectives: To construct a single-cell atlas to define the cellular and molecular constituents driving pathophysiology in PVOD. Methods: Lung samples were collected from four idiopathic non- EIF2AK4 mutation pediatric and adult PVOD patients and age-matched controls. Analyses of single-cell RNA sequencing, Xenium spatial transcriptomics, and immunohistochemistry were performed to identify cell state changes and differential gene expression between controls and PVOD and subsequent transcriptome comparison between our PVOD and published pulmonary arterial hypertension (PAH) datasets. Measurement and Main Results: The single-cell atlas reveals marked changes in the PVOD endothelium compared to controls. EndMT and ectopic COL15A1+ systemic venous shunts and pulmonary vein endothelium are hallmarks of PVOD. Molecular analyses reveal activation of the integrated stress response (ISR)/ATF4, TGFβ signaling, MAPK signaling, and BRD4 are potential key players in the pathophysiology of PVOD. While PVOD and PAH share both pathological and some molecular mechanisms, ISR and TGFβ signaling are more prominent in PVOD than PAH. Conclusions: These data indicate that endothelial dysfunction is a primary etiology in the development of PVOD with activation of multiple pathways with druggable targets. At a Glance Commentary: Scientific Knowledge of the Subject: Pulmonary veno-occlusive disease (PVOD) is driven by progressive vasculopathy of the pulmonary veins and capillaries that results in significant pre-lung transplant mortality. Only 30% of PVOD cases can be explained by genetic mutations in EIF2AK4 , a critical protein translation factor associated with the integrated stress response. Thus, the majority of PVOD cases have no known molecular and cellular etiologies. What This Study Adds to the Field: This study generated a cell atlas of idiopathic PVOD in patients with the more common, non- EIF2AK4 mutation etiology. This cell atlas defines pathological cell state changes in the lung vasculature including aberrant populations in the endothelium of veins and capillaries. These data also provide key insight into the molecular underpinnings driving PVOD disease and identified both novel and common targetable pulmonary vascular disease pathways with known drugs that are currently under investigation or FDA approved.